Cartesian Therapeutics(RNAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNAC Cartesian Therapeutics

Trading 12-22 14:34:09 EST

6.84

-0.38

-5.20%

High7.23	Low6.78	Vol97.22K
Open7.23	D1 Closing7.22	Amplitude6.23%
Mkt Cap177.97M	Tradable Cap64.27M	Total Shares26.00M
T/O680.89K	T/O Rate1.04%	Tradable Shares9.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RNAC","market":"US","secType":"STK","nameCN":"Cartesian Therapeutics","latestPrice":6.8442,"timestamp":1766431945944,"preClose":7.22,"halted":0,"volume":97220,"delay":0,"floatShares":9390341,"shares":26003606,"eps":-1.874951,"marketStatus":"Trading","change":-0.3758,"latestTime":"12-22 14:34:09 EST","open":7.23,"high":7.23,"low":6.78,"amount":680892.13084,"amplitude":0.062327,"askPrice":6.87,"askSize":405,"bidPrice":6.8,"bidSize":685,"shortable":3,"etf":0,"ttmEps":-1.874951,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"listingDate":1466568000000,"exchange":"NASDAQ","adjPreClose":7.22,"preHourTrading":{"tag":"盘前","latestPrice":7.36,"preClose":7.22,"latestTime":"09:19 EST","volume":30,"amount":218.4,"timestamp":1766413185013},"postHourTrading":{"tag":"盘后","latestPrice":7.22,"preClose":7.22,"latestTime":"16:46 EST","volume":12036,"amount":86900.436,"timestamp":1766180779121},"volumeRatio":0.527171,"impliedVol":0.6804,"impliedVolPercentile":0.4104},"requestUrl":"/m/hq/s/RNAC/tweets","defaultTab":"tweets","newsList":[{"id":"2592182561","title":"Cartesian Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Adrian Ion Bot","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182561","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182561?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:04","pubTimestamp":1766095447,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Adrian Ion Bot as the beneficial owner, who serves as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL8wtky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Cartesian Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Adrian Ion Bot","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2592950181","title":"Cartesian Therapeutics Announces the Appointment of Adrian BOT to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592950181","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592950181?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:05","pubTimestamp":1766091900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA5TRWFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2592181998","title":"Press Release: Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592181998","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592181998?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:05","pubTimestamp":1766091900,"startTime":"0","endTime":"0","summary":"FREDERICK, Md., Dec. 18, 2025  -- Cartesian Therapeutics, Inc.  , a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company's Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science and Technology Committee of the Board.\"Dr. Bot brings a unique perspective shaped by pioneering work in first-in-class CAR T cell therapies, including the recent historic acquisition of Capstan's novel in-vivo CAR T technology by Abbvie, as well as the development of next generation RNA-based precision medicines, \" said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. \"His dynamic expertise will be particularly valuable while we continue to advance our current pipeline and explore potential opportunities beyond ex-v","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2590590968","title":"Independent Director of Cartesian Therapeutics Picks Up 168% More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2590590968","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590590968?lang=en_us&edition=fundamental","pubTime":"2025-12-11 18:29","pubTimestamp":1765448959,"startTime":"0","endTime":"0","summary":"Potential Cartesian Therapeutics, Inc. ( NASDAQ:RNAC ) shareholders may wish to note that the Independent Director...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnac/cartesian-therapeutics/news/independent-director-of-cartesian-therapeutics-picks-up-168","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnac/cartesian-therapeutics/news/independent-director-of-cartesian-therapeutics-picks-up-168","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2590659713","title":"Director Timothy C. Barabe Acquires Common Shares of Cartesian Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590659713","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590659713?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:07","pubTimestamp":1765228069,"startTime":"0","endTime":"0","summary":"Timothy C. Barabe, Director, reported the acquisition of common shares of Cartesian Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL73l7d2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Director Timothy C. Barabe Acquires Common Shares of Cartesian Therapeutics Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2585707128","title":"Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2585707128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585707128?lang=en_us&edition=fundamental","pubTime":"2025-11-22 03:15","pubTimestamp":1763752523,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on RNAC stock, giving a Buy rating on November 19. Tyler Van Buren has given h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-pivot-and-promising-clinical-data-justify-buy-rating-for-cartesian-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-pivot-and-promising-clinical-data-justify-buy-rating-for-cartesian-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2584229829","title":"Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2584229829","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584229829?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:41","pubTimestamp":1763574060,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Cartesian Therapeutics Inc ::*CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2K1SXx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2584493019","title":"Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584493019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584493019?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:48","pubTimestamp":1763556480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 07:48 ET (12:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2584126948","title":"H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’","url":"https://stock-news.laohu8.com/highlight/detail?id=2584126948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584126948?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:15","pubTimestamp":1763550925,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $30 from $40 and keeps a Buy rating on the shares. The firm say...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-cuts-cartesian-target-calls-shares-mispriced-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-cuts-cartesian-target-calls-shares-mispriced-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2584963286","title":"Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584963286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584963286?lang=en_us&edition=fundamental","pubTime":"2025-11-19 04:30","pubTimestamp":1763497819,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Cartesian Therapeutics (RNAC – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-and-galmed-pharmaceuticals-glmd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-and-galmed-pharmaceuticals-glmd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LU0128526141.USD","XLV","BK4137","BK4581","XBI","GLMD","BK4139","BK4588","RNAC","LABU","LU0029874061.USD","BK4585"],"gpt_icon":0},{"id":"2584262466","title":"Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584262466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584262466?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:30","pubTimestamp":1763386222,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Athira Pharma (ATHA – Research Report) and Cartesian Therapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-athira-pharma-atha-and-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-athira-pharma-atha-and-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4588","BK4137","LU0029874061.USD","BK4139","ATHA","XBI","BK4585","LABU","BK4007","HCSG","XLV","LU0128526141.USD","BK4581"],"gpt_icon":0},{"id":"2583685787","title":"Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2583685787","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583685787?lang=en_us&edition=fundamental","pubTime":"2025-11-15 02:02","pubTimestamp":1763143320,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics, Inc.  on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus .SLE is a chronic autoimmune disease where the body’s immune system attacks healthy tissues and organs, causing inflammation in various parts of the body, including joints, skin, kidneys, and the brain.Initial data reported a significant reduction in disease activity following initial Descartes-08 treatment, with 100% of participants who reached Month 3 follow-up (n=3) achieving Lupus Low Disease Activity State response.Disease remission was seen in 2 out of 3 participants at Month 3.At this time, Cartesian plans to pause further development of Descartes-08 in SLE, including enrollment in the Phase 2 trial, to prioritize the opportunities in myasthenia gravis, currently in Phase 3, and myositis.Cartesian announced the planned expansion of Descartes-08 into myositis.In this trial, no significant adverse e","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/14/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/14/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["RNAC","BK4139","SLE","BK4077"],"gpt_icon":0},{"id":"2583825683","title":"Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583825683","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583825683?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:55","pubTimestamp":1763139359,"startTime":"0","endTime":"0","summary":"In a report released today, Martin Fan from Wedbush maintained a Buy rating on Cartesian Therapeutics, with a price target of $38.00. Fan covers th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"1111034348","title":"Top Calls on Wall Street: Nvidia, Applied Materials, Nu Holdings, Lowe's, Shake Shack, Gap & More","url":"https://stock-news.laohu8.com/highlight/detail?id=1111034348","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111034348?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:17","pubTimestamp":1763137069,"startTime":"0","endTime":"0","summary":"Here are the biggest calls on Wall Street on Friday:Susquehanna raised $Nu Holdings Ltd(NU)$ price target from $17 to $19. Susquehanna analyst James Friedman maintained a Positive rating. Nu Holdings...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LOW","ORIC","RNAC","GAP","AMAT","NVDA","SHAK","NU"],"gpt_icon":1},{"id":"2583350076","title":"Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583350076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583350076?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:45","pubTimestamp":1763135123,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum of Needham maintained a Buy rating on Cartesian Therapeutics, retaining the price target of $40.00. Gil Blum’s rating is based on ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-realignment-boosts-cartesian-therapeutics-prospects-gil-blum-issues-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-realignment-boosts-cartesian-therapeutics-prospects-gil-blum-issues-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2583099575","title":"Cartesian Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2583099575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583099575?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:21","pubTimestamp":1763126460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 08:21 ET (13:21 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2583497505","title":"Cartesian Therapeutics price target raised to $44 from $42 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2583497505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583497505?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:30","pubTimestamp":1763123428,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Cartesian Therapeutics (RNAC) to $44 from $42 and keeps a Buy rating on the shares. The firm cites the compa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-price-target-raised-to-44-from-42-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-price-target-raised-to-44-from-42-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2583523971","title":"Cartesian Therapeutics Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583523971?lang=en_us&edition=fundamental","pubTime":"2025-11-14 12:12","pubTimestamp":1763093575,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics, Inc. ( ($RNAC) ) has released its Q3 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presente...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2583951734","title":"Cartesian Therapeutics Reports Promising Phase 2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583951734","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583951734?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:35","pubTimestamp":1763069710,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics ( ($RNAC) ) has shared an announcement. On November 13, 2025, Cartesian Therapeutics announced promising initial data from i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-promising-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-promising-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2583831514","title":"Cartesian Therapeutics Inc - Cartesian Plans to Pause Further Development of Descartes-08 in Sle","url":"https://stock-news.laohu8.com/highlight/detail?id=2583831514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583831514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUABFMZPX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.selectabio.com","stockEarnings":[{"period":"1week","weight":-0.1526},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.2352},{"period":"6month","weight":-0.2602},{"period":"1year","weight":-0.6253},{"period":"ytd","weight":-0.5969}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.069643},{"month":2,"riseRate":0.555556,"avgChangeRate":0.002515},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.091249},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.088422},{"month":5,"riseRate":0.666667,"avgChangeRate":0.155539},{"month":6,"riseRate":0.444444,"avgChangeRate":0.054888},{"month":7,"riseRate":0.3,"avgChangeRate":-0.074772},{"month":8,"riseRate":0.7,"avgChangeRate":0.054751},{"month":9,"riseRate":0.5,"avgChangeRate":0.015696},{"month":10,"riseRate":0.5,"avgChangeRate":-0.020193},{"month":11,"riseRate":0.5,"avgChangeRate":-0.029903},{"month":12,"riseRate":0.2,"avgChangeRate":-0.1074}],"exchange":"NASDAQ","name":"Cartesian Therapeutics","nameEN":"Cartesian Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cartesian Therapeutics(RNAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cartesian Therapeutics(RNAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cartesian Therapeutics,RNAC,Cartesian Therapeutics股票,Cartesian Therapeutics股票老虎,Cartesian Therapeutics股票老虎国际,Cartesian Therapeutics行情,Cartesian Therapeutics股票行情,Cartesian Therapeutics股价,Cartesian Therapeutics股市,Cartesian Therapeutics股票价格,Cartesian Therapeutics股票交易,Cartesian Therapeutics股票购买,Cartesian Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cartesian Therapeutics(RNAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cartesian Therapeutics(RNAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction